Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Ketesse tablets

Marketed by Ferron Par Pharmaceuticals

Ingredients in every tablet

Dexketoprofen 25 mg

Each package contains

5 strips of 10 tablets

Dosage form

tablet

Dosage formTablet; coated

Flavour

None

W.H.O. classification

N02B
N02B

A.T.C. Level 1

Anatomical Main group

N - Nervous system
N02B

A.T.C. Level 2

Therapeutic subgroup

N02 - Analgesics
N02B

A.T.C. Level 3

Pharmacological subgroup

N02B - Other Analgesics and Antipyretics in ATC

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

NOT RECOMMENDEDThis item should not be used while operating heavy machinery.

Pregnancy

NOT RECOMMENDEDThis item is not safe for use during pregnancy.

Lactation

NOT RECOMMENDEDThis item is not safe for use during lactation.

Indication

Pain symptoms of mild to moderate intensity
Treatment of pain symptoms with mild to moderate intensity e.g. acute musculoskeletal pain, dysmenorrhea, dental pain and postoperative pain. (IPHA p.2, Medscape p.1, PI Ketesse, Product Monograph-2 p.48, Product Profile Tablet p.35, SPC p.1)

Dosage

0 TO 18 YEARS OLD
The safety and efficacy Ketesse in children have not been established and the product should not be used in children.

Ketesse film-coated tablet are not intended for long term use and the treatment must be limited to the symptomatic period.

18 TO 65 YEARS OLD
According to the nature and severity of pain, the recommended dosage is generally 12.5 mg every 4-6 hours or 25 mg every 8 hours. The total daily dose should not exceed 75 mg.

Ketesse film-coated tablet are not intended for long term use and the treatment must be limited to the symptomatic period.

65 YEARS OLD AND ABOVE
It is recommended to start the therapy at the lower end of the dosage range (50 mg total daily dose). The dosage may be increased to that recommended for the general population only after good general tolerance has been ascertained.

Ketesse film-coated tablet are not intended for long term use and the treatment must be limited to the symptomatic period.

PATIENTS WITH HEPATIC DYSFUNCTION
Patients with mild to moderate hepatic dysfunction should start therapy at reduced doses (50 mg total daily doses) and be closely monitored. Ketesse film-coated tablet should not be used in patients with severe hepatic dysfunction.

PATIENTS WITH RENAL DYSFUNCTION
The initial dosage should be reduced to 50 mg total daily dose in patients with mildly impaired renal function. Ketesse film-coated tablet should not be used in patients with moderate to severe renal dysfunction.